Meeting
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
Presenter
Tom Stinchcombe, MD
Duke Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04579380
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3151)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3151
Abstract #
TPS3151
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Chair
Speaker: Alina Basnet, MD, MBBS
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress).
Speaker: Matt D. Galsky, MD, FASCO
Videos & Slides
2021 Genitourinary Cancers Symposium
SGNTUC-019: Phase II basket study of tucatinib (TUC) and trastuzumab (Tras) in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (trial in progress).
Speaker: Evan Y. Yu, MD
Videos & Slides
2024 ASCO Annual Meeting
Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.
Speaker: Paula R Pohlmann, MD, PhD